Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization
Growth Hormone and Dehydroepiandrosterone Effect on Poor Ovarian Reserve Patients During in Vitro Fertilization
Beni-Suef University
165 participants
Oct 10, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this study is to evaluate the role of Somatropin and Dehydroepiandrosterone (DHEA) on ovarian reserve parameters and intracytoplasmic sperm injection (ICSI) outcome in poor ovarian responder. The main question it aims to answer is: Which intervention is more effective in increasing number and size of follicles? Participants will be followed 1 month before starting induction in growth hormone and 12 weeks for DHEA and through intracytoplasmic sperm injection (ICSI) cycle.
Eligibility
Inclusion Criteria4
- At least two of the following three criteria had to be present after maximal stimulation:
- Advanced maternal age (\>40 years) or any other risk factor for Poor Ovarian Response (POR).
- ≤3 oocytes with a conventional stimulation protocol).
- An abnormal ovarian reserve test \[i.e. antral follicle count (AFC) less than 5-7 follicles or anti-Müllerian hormone (AMH) below 0.5-1.1 ng/ml\].
Exclusion Criteria3
- Any endocrine or metabolic disorder such as hyperprolactinemia, diabetes and thyroid dysfunction.
- Any pelvic pathology such as hydrosalpinx, uterine anomaly.
- Any male factor infertility such as Oligo-Astheno-Teratozoospermia (OAT) or azoospermia
Interventions
Patients will receive Somatropin (4IU for 1 month)1 S.C injection every 3 days for at least 1 month plus, folic acid 400 mcg per day.
Patients will receive DHEA 50 mg twice per day for 12 weeks plus folic acid 400mcg per day
Patients will receive folic acid 400 mcg per day
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07323329